NCT00586339View on ClinicalTrials.gov

Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females

PHASE2CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

January 17, 2008

Primary Completion Date

July 18, 2011

Study Completion Date

July 18, 2011

Conditions

Infections, Papillomavirus

Interventions

BIOLOGICAL

Cervarix

Intramuscular injection, 3 doses

BIOLOGICAL

Placebo Control

Intramuscular injection, 3 doses

Trial Locations (1)

7784

GSK Investigational Site, Khayelitsha

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY